2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173384
    DSPE-DOTA sodium
    DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases.
    DSPE-DOTA sodium
  • HY-173399
    hSTING activator-1
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-173404
    VB-85247
    VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.
    VB-85247
  • HY-173407
    P2Y14R antagonist 4 3081687-67-1
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
    P2Y14R antagonist 4
  • HY-173409
    AR antagonist 11 3005979-40-5
    AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC50 of 0.019 μM. AR antagonist 11 is also effective against ARF877L/T878A mutant (IC50: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC50: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa).
    AR antagonist 11
  • HY-173410
    iNOs-IN-6
    iNOs-IN-6 is an anti-inflammatory agent. iNOs-IN-6 inhibits NF-κB, iNOS, and MAPK expression(IC50: 0.2-0.62 μM). iNOs-IN-6 reduces IL-6, TNF-α, and IL-1β pro-inflammatory mediators levels (IC50: 0.4-0.69 μM).
    iNOs-IN-6
  • HY-173411
    DNJ-20 3081926-49-7
    DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.
    DNJ-20
  • HY-173414
    PROTAC STING degrader-3
    PROTAC STING degrader-3 (Compound ST9) is a STING PROTAC degrader (DC50: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) (Pink: STING ligand (HY-47709); Blue: E3 ligase CRBN ligand (HY-41547); Black: linker).
    PROTAC STING degrader-3
  • HY-173416
    Anti-inflammatory agent 100
    Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory agent. Anti-inflammatory agent 100 inhibits MAPK and NF-κB signaling, and also inhibits NF-κB pathway by suppressing the phosphorylation of IκB-α and blocking nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 inhibits NO production (IC50: 0.5 μM) and TNF-α, IL-6, IL-1β secretion.
    Anti-inflammatory agent 100
  • HY-173425
    STING-IN-15 2912492-05-6
    STING-IN-15 (compound 66) is a potent STING inhibitor. STING-IN-15 inhibits human STING and mouse STING with IC50s of 116 and 96.3 nM, respectively. STING-IN-15 significantly alleviates tissue injury and inflammation in TREX1 D18N mouse model.
    STING-IN-15
  • HY-173443
    SP-C01 2982533-42-4
    SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation.
    SP-C01
  • HY-173445
    RIPK1-IN-30
    RIPK1-IN-30 (compound 24) is a potent RIPK1 inhibitor with an IC50 of 2.01 μM. RIPK1-IN-30 exhibits protective effects in HT-29 cell model of TSZ-induced necroptosis with an EC50 of 6.77 μM.
    RIPK1-IN-30
  • HY-173450
    ZL0516 2230496-93-0
    ZL0516 is a potent, selective, and orally active BRD4 BD1 inhibitor. ZL0516 suppresses inflammatory bowel disease (IBD) by inhibiting BRD4/NF-κB signaling.
    ZL0516
  • HY-173454
    RIPK2/3-IN-2
    RIPK2/3-IN-2 (29) is a dual RIPK2 and RIPK3 inhibitor, with IC50 values of 12 nM and 18 nM, respectively. RIPK2/3-IN-2 (29) induces necroptosis, with an EC50 of 0.16 μM.
    RIPK2/3-IN-2
  • HY-173466
    LT-188A 2922530-99-0
    LT-188A is a potent TGR5 agonist with an EC50 of 23 μM. LT-188A decreases the levels of inflammatory mediators in macrophages.
    LT-188A
  • HY-173483
    ATX inhibitor 26 2940248-11-1
    ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with anIC50 of 57 nM in human plasma. ATX inhibitor 26 inhibits cell migration and collagen gel contraction. ATX inhibitor 26 has significant anti-fibrotic effects, reducing collagen deposition in a Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis model.
    ATX inhibitor 26
  • HY-173486
    BuChE-IN-21
    BuChE-IN-21 (compound SXF3) is a potent and selective BuChE inhibitor. BuChE-IN-21 inhibits eqBuChE and hBuChE with IC50s of 0.05 and 0.04 μM, respectively. BuChE-IN-21 has high anti-inflammatory activity.
    BuChE-IN-21
  • HY-173487
    COX-2-IN-53
    COX-2-IN-53 (compound 9) is a potent COX-2 inhibitor with an IC50 of 0.373 μM. COX-2-IN-53 reduces radiation-induced oxidative stress.
    COX-2-IN-53
  • HY-173491
    CXCR2/CCR7 antagonist-1 473728-04-0
    CXCR2/CCR7 antagonist-1 (compound 6) is a potent CXCR2 and CCR7 dual antagonist with IC50s of 0.0046 and 0.0014 μM, respectively. CXCR2/CCR7 antagonist-1 can be used in the study of cancer metastasis and autoimmune diseases.
    CXCR2/CCR7 antagonist-1
  • HY-173497
    IRE1-IN-2
    IRE1-IN-2 (compound G15) is a potent IRE1 inhibitor. IRE1-IN-2 inhibits FFA-induced lipid accumulation with an IC50 of 2.06 μM.
    IRE1-IN-2
Cat. No. Product Name / Synonyms Application Reactivity